Telaglenastat is an orally bioavailable glutaminase inhibitor under investigation as an antineoplastic agent. It selectively and irreversibly inhibits the mitochondrial enzyme glutaminase, impairing glutamine metabolism in rapidly proliferating cells.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1439399-58-2
Barbital sodium
pharmaceutical raw material
Trihexyphenidyl
pharmaceutical raw material
Piperazine citrate
pharmaceutical raw material
Sulfathiazole sodium
pharmaceutical raw material
N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
PRAAPINBUWJLGA-UHFFFAOYSA-N
C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F